Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Piper Sandler
Research analysts at Piper Sandler began coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) in a note issued to investors on Friday, MarketBeat Ratings reports. The brokerage set a “neutral” rating and a $46.00 price target on the stock. Piper Sandler’s target price points to a potential upside of 17.20% from the […]
More Stories
How Inventory Allocation Across Multiple Warehouses Can Reduce Delivery Times and Costs
A shopper in Seattle orders a pair of running shoes. Whether that package arrives quickly and cheaply depends on a...
Wall Street Review: Small Caps Outperform as Bond Yields Ease
By Panos Mourdoukoutas Small-cap stocks outperformed this week as investors rotated out of the volatile AI trade and into interest-rate-sensitive...
Judge Rejects Bail for Former OpenAI Employee Accused of Installing Listening Device
By Lear Zhou SAN FRANCISCO—A federal judge rejected a bail request of a former OpenAI engineer who was accused of...
Trump Announces $4.2 Billion Audi Auto Manufacturing Investment in Georgia
By Travis Gillmore PERRY, Ga.– President Donald Trump unveiled a $4.2 billion investment from automaker Audi to develop its first...
DOJ Gives California County Election Officials 48 Hours to Help Verify Voters’ Citizenship
By Tom Gantert The U.S. Department of Justice has sent letters to county election officials in California warning them they...
French Officials Say 1,300 Arrests Made Amid Latest Unrest
By Jack Phillips More than 1,300 people were arrested in another day of protests and riots, after a mass march...